OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
Lusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of treatment in the randomized, double-blind CoTikiS Phase 2 study. These results were presented in the Top 10 congress highlights oral plenary session at ECCO 2025.
Lusvertikimab demonstrated high rates of clinical and endoscopic remission after 10 weeks of treatment, along with clinically meaningful histological improvement and Histo-Endoscopic Mucosal Improvement (HEMI) rates.
Treatment with Lusvertikimab significantly reduced fecal calprotectin (FCP) after 10 weeks of treatment, an objective biomarker of mucosal inflammation in UC patients and an early predictor of endoscopic and histological responses.
Statistically significant efficacy was demonstrated in clinical and endoscopic remission in the UC patient subgroup with high baseline FCP (>250µg/g).
A good safety and tolerability profile was observed with no clinically relevant safety signals.
NANTES, France – February 24, 2025, 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), presented full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of Lusvertikimab (OSE-127) in the Oral and Poster presentations at the 20th Congress of ECCO (European Crohn's and Colitis Organisation), demonstrating meaningful efficacy and a favorable safety profile in moderate to severe active UC patients.
Pr. Arnaud Bourreille, Associate Professor in Gastroenterology at the Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, and Coordinating Investigator of the CoTikiS study, said: 'These full Phase 2 clinical induction results provide strong efficacy data for Lusvertikimab in UC, particularly highlighting the meaningful achievement in the key endpoints of endoscopic remission and histological improvement after only 10 weeks of treatment. The latest data showing high histo-endoscopic mucosal improvement (HEMI) and mucosal healing rates represent a strong signal of efficacy, as they are associated with the prediction of long-term prevention of future relapse and are important for UC patients in need of breakthrough therapeutic options and sustained healing.'
Pr. Walter Reinisch, Director of the IBD Study Group at the Medical University of Vienna, Department of Internal Medicine, Vienna, Austria, commented: 'Lusvertikimab has been shown to significantly decrease FCP, an objective inflammatory biomarker most commonly used in clinical practice to monitor treatment response in patients with ulcerative colitis. These data parallel and confirm the overall results of the primary and secondary endpoints from the CoTikiS study, highlighting the potential of Lusvertikimab as an efficacious therapy for all UC patients, also by normalising increased baseline FCP values.'
Week-10 Induction Period Results in the Global Population1
The randomized, double-blind Phase 2 clinical trial CoTikiS evaluated the efficacy and safety of Lusvertikimab versus placebo in 136 patients with moderate to severe active UC who failed or lost response to previous treatment(s)2. CoTikiS is a 50-week study, with a 10-week induction period evaluating two doses (450 mg or 850 mg) of Lusvertikimab against placebo, a 24-week open-label extension period (OLE) during which subjects received Lusvertikimab 850 mg infusions every four weeks and a 16-week safety follow-up period free of treatment. The induction data at week 10 in the full population and in the subgroup of severe UC patients with high baseline FCP were presented at ECCO 2025.
The overall induction results from the CoTikiS study show that the two doses evaluated, 450 mg and 850 mg, met the primary efficacy endpoint (Modified Mayo Score) at week 10 and demonstrated statistically significant and clinically meaningful results on secondary endpoints:
Primary End Point at Week 103
Improvement of the Global Disease Activity Index of UC (Modified Mayo Score)
Lusv 450mg group: difference of -1.16 point versus placebo (p= 0.019)
Lusv 850mg group: difference of -0.9 point versus placebo (p=0.036)
450 + 850mg pooled group: difference of -1.00 point versus placebo (p= 0.010)
Secondary Endpoints at Week 10, included:
Clinical remission rate: 16% for the pooled 450+850 mg group (n=85) versus 4% for placebo (n=49) (Odds ratio = 4.25; p=0.066)
Endoscopic improvement rate: 32% for the pooled group versus 13% for placebo (Odds ratio = 3.29; p=0.027)
Endoscopic remission rate: 25% for the pooled group versus 13% for placebo (Odds ratio = 2.33; p=0.120)
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) mean score change: -1.35 for the pooled group versus -0.32 for placebo (p=0.007)
Fecal Calprotectin (FCP): +189 µg/g for the placebo group, -830 µg/g for the 450mg group (p = 0.009), -635 µg/g for the 850mg group (p=0.018), and -716 μg/g for the pooled group (p=0.004)
Exploratory objectives included histological score analysis (centralized and blinded), such as the number and proportion of patients with histological improvement at Week 10, defined by a Nancy Histological Index (NHI) score of 0 or 1, and the number and proportion of patients with histo-endoscopic mucosal improvement at week 10, defined by a NHI ≤ 1 with a Mayo Endoscopic score ≤ 1. Additional histological readouts included Robarts' histological index (RHI) and Geboes score (GS) changes from baseline.
Histological Improvement (NHI score ≤ 1) at W10: Chi-square p < 0.01
45.2% in the 450 mg group (n=31); difference versus placebo of 35.2% (p<0.01)
31.0% in the 850 mg group (n=42); difference versus placebo of 21.0% (p=0.02)
37.0% in the 450 + 850 mg pooled group (n=73); difference versus placebo of 27.0% (p<0.01)
10.0% in the placebo group (n=40)
Histo-Endoscopic Mucosal Improvement (HEMI) (NHI score ≤ 1 + MES ≤ 1) at W10: Chi-square p = 0.02
32.3% in the 450 mg group; difference versus placebo of 24.8% (p<0.01)
14.3% in the 850 mg group; difference versus placebo of 6.8% (p=0.33)
21.9% in the 450+850 mg pooled group; difference versus placebo of 14.4% (p=0.05)
7.5% in the placebo group
Histological Geboes score (GS) mean changes from baseline at W10: Chi-square p = 0.05
450 mg group: -2.9 (SD: 7.2)
850 mg group: -4.2 (SD: 6.1; p<0.01 versus placebo)
450+850 mg pooled group: -3.7 (SD: 6.6; p=0.02 versus placebo)
Placebo: -0.7 (SD: 5.1)
Histological Robarts Index (RHI) mean changes from baseline at W10: Chi-square p < 0.01
450 mg group: -3.5 (SD: 12.3)
850 mg group: -8.5 (SD: 10.8; p<0.01 versus placebo)
450+850 mg pooled group: -6.4 (SD: 11.7; p=0.01 versus placebo)
Placebo: -0.6 (SD: 9.2)
Week-10 Induction Results in Severe Active UC with High Baseline Fecal Calprotectin
Fecal calprotectin (FCP) is an objective marker of inflammation in UC patients and may predict sustained clinical and endoscopic response. The CoTikiS study included an exploratory endpoint assessing the efficacy of Lusvertikimab 850 mg and 450 mg compared to placebo in patients with FCP > 250 μg/g at baseline, considered the threshold for active and severe inflammatory UC disease.
High baseline FCP (> 250 μg/g) represented 69.5% (n=93) of the total Phase 2 population. Baseline FCP was not different between treatment groups. These additional analyses have shown that Lusvertikimab significantly decreased FCP after 10 weeks of treatment in both dose groups and achieved improvements in clinical and endoscopic outcomes in this UC patient population with active inflammation. These data strengthen the overall results of the primary and key secondary endpoints from the CoTikiS study.
Fecal Calprotectin (FCP) decreases at W10
450 mg group: difference of -1 169 μg/g versus placebo (p=0.025)
850 mg group: difference of -966 μg/g versus placebo (p=0.034)
450+850 mg pooled group: difference of -1 048 μg/g versus placebo (p=0.011)
Fecal Calprotectin (FCP) normalization to below 250 µg/g at W10
38% in the 450 mg group (n=22); difference versus placebo of 20% (p=0.1)
45% in the 850 mg group (n=33); difference versus placebo of 27% (p=0.02)
42% in the 450+850 mg pooled group (n=55); difference versus placebo of 24% (p=0.02)
18% in the placebo group (n=38)
Improvement of the Global Disease Activity Index of UC (MMS)
450 mg group; difference of -1.47 point versus placebo (p= 0.011)
850 mg group; difference of -0.95 point versus placebo (p=0.055)
450 + 850 mg pooled group; difference of -1.16 point versus placebo (p= 0.009)
Clinical Remission rate at W10: Fisher-test p < 0.01
28.3% in the 450 mg group; difference versus placebo of 28.3%
9.4% in the 850 mg group; difference versus placebo of 9.4%
16.9% in the 450+850 mg pooled group; difference versus placebo of 16.9%
0% in the placebo group
Endoscopic Remission rate at W10
38% in the 450 mg group; difference versus placebo of 30.5% (p= 0.03)
14% in the 850 mg group; difference versus placebo of 6.7% (p= 0.33)
24% in the 450+850 mg pooled group; difference versus placebo of 16.3% (p= 0.11)
7% in the Placebo group
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) mean score change from baseline
450 mg group; difference of -1.69 point versus placebo (p= 0.003)
850 mg group; difference of -0.74 point versus placebo (p=0.12)
450+850 mg pooled group; difference of -1.12 point versus placebo (p= 0.01)
Safety Profile
Lusvertikimab displayed a good safety profile and was well tolerated, with no difference between both dose groups and placebo in the incidence of drug-related serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, drug-related AE and severe drug-related AEs, opportunistic infections, or infusion reactions during the induction period.
ABOUT ULCERATIVE COLITIS (UC)Ulcerative colitis is a chronic disease of the large intestine, or colon, and rectum, in which the lining of the gastrointestinal tract becomes inflamed and develops ulcers. This condition is the result of an overactive immune system. UC affects 3.3 million patients in the US, Europe and Japan (1). Despite broad therapeutic options, remission rates are only 25-30%, (2) leaving most patients without satisfactory treatments. 15% of patients (3) fail to respond to all therapies and undergo surgery as a last option. (1) EvaluatePharma (2) Drugs Context. 2019; 8: 212572 –doi: 10.7573/dic.212572 (3) Scientific Reports volume 10, Article number: 12546 (2020)ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Click and follow us on X and LinkedInContacts
Fiona Olivierfiona.olivier@ose-immuno.comSylvie Détrysylvie.detry@ose-immuno.com
France Media Contact FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561
Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
1 An interim futility analysis performed early (approx. 30% of patients) by the IDMC proposed stopping the 450 mg group due to the risk of futility. The 850 mg group was initially considered as the primary analysis; however, in the final analysis, the futility of the 450mg dose group was not confirmed. Statistical Analysis Plan (SAP) Addendum: results of 450mg group of patients were included in the analyses. In addition, the two groups were pooled for the active drug cohort to evaluate a global treatment effect.
2 Previous corticosteroids, immunosuppressive agents or previous biological treatments.3 OSE Immunotherapeutics Press Release of November 4th 2024: EN_241104_Lusvertikimab-Phase-2.pdf
Attachment
EN_250224_ECCO Clinical presentation_FINAL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
5 days ago
- CBS News
3 young peregrine falcons on Pitt's Cathedral of Learning fledge the nest
Something Good: Carla, the peregrine falcon laid her first egg of the year Something Good: Carla, the peregrine falcon laid her first egg of the year Something Good: Carla, the peregrine falcon laid her first egg of the year The three young peregrine falcons that hatched on top of Pitt's Cathedral of Learning this spring have fledged the nest. The National Aviary says the three siblings will continue to hang around the nest as they grow comfortable flying and hunting on their own. Before the juveniles fledged, viewers of the National Aviary's FalconCam could see them taking turns on the edge of the nest box, exercising their wings as they prepared for their first flights. Later this year, after they've gained all the skills they need to survive on their own, the young falcons will take off. Since the birds were recently banded by the Pennsylvania Game Commission, scientists will be able to track their next moves. "Whether they remain local or move to another bridge, cliff, or skyscraper rooftop in Pennsylvania or another nearby state, we should be able to tell where they end up, when they mate, and if they are surviving and thriving in their new homes," the National Aviary said on its website. (Photo: Mike Faix) Viewers of the FalconCam have been watching Carla and Ecco's chicks since they hatched at the end of April. While Ecco has been at the Cathedral of Learning since 2020, Carla first appeared in 2023, and the couple had their first brood last year. Those two chicks were also banded. Peregrine falcons were formerly endangered in Pennsylvania because of the use of the agricultural pesticide DDT. Banding the chicks helps scientists study the behavior of falcons while determining the current status of their populations.
Yahoo
7 days ago
- Yahoo
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Figure_1 OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, leveraging a new predictive biomarker. Leads a new era in cancer vaccines with Tedopi® on track for registration. Drives company transformation through responsible governance: international development, rigorous financial planning and clinical execution. NANTES, France – June 4th, 2025, 8:00 am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today outlined the company's ambition for long-term growth and sustainable shareholder and societal value. Nicolas Poirier, CEO of OSE Immunotherapeutics notes: "OSE's grounding in solid science, our collaborative approach and a skilled workforce have resulted in a transformative two years, progressing our mission to bring breakthrough immunotherapies to the clinic. We are proud of our accomplishments, particularly delivering positive results for our lead assets, lusvertikimab and Tedopi®, which hold the potential to redefine standards of care across multiple diseases in I&I and I/O. We also secured new partnerships for our preclinical programs and significantly strengthened our financial position with over €90 million in new non-dilutive funding. OSE is positioned among Europe's leading biotechs. Now, it's time to build a more ambitious international company and unlock greater long-term value for all stakeholders.' OSE Immunotherapeutics' Board of Directors, led by Chairman, Didier Hoch, commented: 'Under the joint leadership of the Board and Executive Team, OSE has shown resilience and growth in a competitive biotech landscape. The company is entering a decisive phase. Our strategy is built on three pillars: maintaining scientific leadership, expanding strategic alliances, and ensuring disciplined financial management for sustainable growth. To achieve this, the company will explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing. We are shaping the future by building an ambitious international biotech, driven by innovation creating lasting value for patients, employees, and shareholders.' New predictive biomarker with potential to revolutionize UC treatment, an emerging value lever for lusvertikimab Despite intensive therapeutic research in IBD, only 25–30% of UC patients currently achieve clinical remission, and this limitation—commonly referred to as the therapeutic ceiling (Vieujean S. Nature Reviews Gastroenterology, 2025)—persists across all approved therapies and drug classes in late-stage development. OSE research and translational teams, in collaboration with foundational model specialists, have identified a predictive biomarker that can isolate a subpopulation of patients (~30%) and offer significantly enhanced treatment outcomes, potentially achieving clinical remission rates exceeding 50%. This biomarker-driven approach was developed using advanced AI and transfer learning. The model was trained on multimodal data from millions of chronic inflammatory disease patients and refined with data from CoTikiS Phase 2 study. Importantly, biomarker-negative patients showed 0% clinical remission in this dataset, indicating no loss of treatment opportunity when prioritizing treatment based on biomarker status. This precision medicine approach could position lusvertikimab as a first-line therapy for the biomarker-positive population; a potential addressable market opportunity exceeding $3 billion across seven major markets. Next steps include prospective validation of this predictive biomarker through stratification in future clinical trials. Nicolas Poirier details: 'Our comprehensive dataset for lusvertikimab, with its novel upstream mechanism demonstrating clinical efficacy and good safety supports development in UC and other autoimmune diseases. The identification of a predictive biomarker is a breakthrough, suggesting that around 30% of UC patients could achieve remission rates over 50%. This reinforces lusvertikimab's potential as a monotherapy in UC and acts as an additional catalyst to accelerate development. We are designing a Phase 2b program to demonstrate efficacy by 2027, establish the dose for registrational studies, explore a subcutaneous formulation, and validate the predictive biomarker.' Commenting on OSE's progress in Tedopi, Nicolas Poirier adds: 'Earlier this week, we shared our progress with Tedopi® (link to press release). To summarize, our pivotal Phase 3 program in NSCLC with Tedopi® is progressing well, keeping us in the race to register the first therapeutic cancer vaccine. Enrolment is advancing across 144 clinical sites in Europe and North America and is on track to complete in the second half of 2026. The data readout is expected in 2027. The recent positive results in pancreatic cancer highlight the growing momentum behind therapeutic cancer vaccines. We are looking forward to additional Phase 2 readouts in combination with anti-PD1 from our ovarian and lung cancer trials in 2026.' Nicolas Poirier concludes: 'OSE is at the forefront of transformative scientific breakthroughs in areas of critical unmet medical need. I am convinced that the company is at a turning-point, with a clear international trajectory toward value creation and long-term impact. With strong science, strategic focus, and a robust diversified pipeline, OSE is uniquely positioned to deliver meaningful returns for shareholders—while transforming outcomes for patients worldwide.' DOCUMENTS MADE AVAILABLE TO SHAREHOLDERSThe convening brochure for the combined shareholders' meeting of June 25, 2025, now available on the Company's website ( is an essential tool for understanding the strategy pursued by the Board of Directors, informing shareholders and facilitating their voting decision. The related press release, presenting the context of the combined shareholders' meeting and the Board's position on all resolutions, is also available here: ABOUT COTIKIS The CoTikiS study, a 50-week randomized, double-blind, placebo-controlled trial, included a 10-week induction period evaluating two doses (450 mg or 850 mg) of lusvertikimab versus placebo; followed by a 24-week open label extension (OLE) with 850 mg infusions every four weeks; and a 16-week safety follow-up. Findings from the induction phase, presented at the 2025 ECCO congress, showed both doses met the primary efficacy endpoint (improvement in Modified Mayo Score at Week 10) and demonstrated significant results on secondary endpoints. The study highlights lusvertikimab's potential as a first-in-class monotherapy with a novel mechanism of action in the treatment of chronic and inflammatory diseases. Clinical and preclinical data were presented at ECCO 2025 and Digestive Disease Week (DDW) in May 2025, showing high rates of clinical and endoscopic remission, histological improvement and Histo-Endoscopic Mucosal Improvement (HEMI) with a favorable safety profile. Early efficacy signals in both biologic-naïve and experienced populations suggest rapid onset of effect, indicating potential as a first-line biologic or for patients resistant to anti-TNF and anti-IL-12/23 therapies. OLE data shows over 90% of UC patients who achieved a clinical response after 10 weeks maintained symptomatic remission for an additional 24 weeks, with 61% of those not in remission after 10 weeks achieving it after a further 24 weeks on the 850 mg dose. Lusvertikimab was well tolerated over the extended treatment period. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments Figure_1 EN_250604_Bold Strategic Vision press release_vf3
Yahoo
02-06-2025
- Yahoo
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical Oncology (ASCO) 2025: TEDOPaM - Phase 2 first positive results in advanced pancreatic cancer: Oral communication presented by the French GERCOR Oncology Group, trial sponsor. ARTEMIA - International pivotal Phase 3 study in Non-Small Lung Cancer (NSCLC): Trial in Progress. NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the 'off-the-shelf' neo-epitope-based therapeutic cancer vaccine under evaluation in both monotherapy and combination therapy across five clinical trials in several cancer indications. Silvia Comis, MD, Chief Clinical and Medical Research Officer OSE Immunotherapeutics, commented: 'We are pleased to share the latest clinical updates on our cancer vaccine Tedopi® at the ASCO Annual Meeting. Tedopi® combines 10 neo-epitopes derived from five tumor antigens, selected for their presence in a range of tumors, offering a multi-target 'pipeline in a product' approach for HLA-A2 positive patients to address unmet needs in oncology. The positive results for Tedopi® in pancreatic cancer are promising for this devastating disease with a poor prognosis. We extend our gratitude to the GERCOR Oncology Group and the PRODIGE Intergroup, sponsors of the TEDOPaM study, for presenting these encouraging results at ASCO. In lung cancer, patient recruitment is progressing per plan in the Artemia Phase 3 registration study, a key milestone bringing us one step closer to the registration of Tedopi® for NSCLC. As previously communicated, the readouts of the combination Phase 2 trials, CombiTED for NSCLC and TEDOVA for ovarian cancer, are expected in 2026.' TEDOPaM - An oral communication, titled (abstract 4009) featuring positive topline Phase 2 results for the clinical trial TEDOPaM was presented by the GERCOR Oncology Group at ASCO 2025. TEDOPaM is a randomized, non-comparative, Phase 2 trial evaluating FOLFIRI1 (Arm A) and cancer vaccine Tedopi® (OSE2101) plus FOLFIRI chemotherapy (Arm B) as maintenance treatment in HLA-A2 positive patients with advanced or metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with no progression after eight cycles of FOLFIRINOX induction chemotherapy2. The primary endpoint of the trial was the one-year overall survival (OS) rate in the experimental Arm B (Fleming 2-stage design, H0: 25%; H1: 50%, 1-sided alpha: 2.5%, power: 90%). 107 patients (53 patients in Arm A and 54 patients in Arm B) were enrolled (NCT03806309). The TEDOPaM trial met its primary objective, showing positive outcomes according to the predefined statistical hypothesis, with a 12-month OS of 65% in Arm B, and minimal toxicity for Tedopi® combined with FOLFIRI as maintenance treatment. Two complete responses were observed when adding Tedopi®. No new safety signal was observed. Prof. Cindy Neuzillet, MD, PhD (Curie Cancer Research Institute, Saint-Cloud), Principal Investigator of the TEDOPaM study stated: 'These results are an encouraging first step towards better understanding the contribution of Tedopi® in combination therapy in advanced pancreatic cancer. We now need more mature data on overall survival over a longer period. A translational and biomarker program is also underway to identify patient profiles likely to benefit from this maintenance treatment involving a neo-epitope-based cancer vaccine. Thanks to the digestive oncology community for their support in this research, which helps us better understand this disease.' Detailed results: A total of 107 patients were randomized between April 2021 and May 2023. The median age was 64 years, with 53% men and 69% having metastases. The median number of Tedopi® injections was 7.5. At the data cut-off on December 9, 2024, the median follow-up was 21 months. The TEDOPaM study met its primary endpoint: M12-OS was 65% in Arm B (FOLFIRI + Tedopi®). With a median follow-up of 21 months, around 35% of death events were observed. An unexpectedly long OS was observed in these PDAC patients with disease control after induction FOLFIRINOX: median OS of 17 months in control Arm A (versus 10-12 months expected). Two complete responses were observed when adding Tedopi® in Arm B, and none in control Arm A with chemotherapy alone. Safety: 26% in Arm B reported serious adverse events (SAEs). 6% related to Tedopi®. No new safety signal was reported. Further follow-up for OS and safety data is ongoing. A comprehensive translational analysis (IMMUNOPANC-Sign program) is ongoing. ARTEMIA - A 'Trial in Progress' poster titled: was also presented at ASCO 2025. The Phase 3 pivotal clinical trial aims to support the registration of Tedopi® as a second-line treatment in HLA-A2 positive NSCLC patients with secondary resistance to anti-PD-(L)1 immunotherapy. This pivotal trial is conducted in 14 countries across the United States, Canada, Europe, and United Kingdom. ARTEMIA will include 363 patients and enrolment is progressing according to the study program (NCT06472245). ABOUT RESECTED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC). Resected pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of cancer originating in the ducts of the pancreas. It represents about 95% of all pancreatic cancers. The global burden of pancreatic cancer has more than doubled in recent decades. It is now the sixth leading cause of cancer-related death worldwide, with an estimated 510,922 new cases and 467,409 deaths in 2022. The incidence of the disease continues to rise annually, with projections indicating a 95.4% increase in new cases by 2050, potentially reaching a total of 998,663 new cases globally. The overall five-year survival rate for pancreatic cancer is 10% worldwide, with only modest improvement in the past decade3. Pancreatic cancer is now the 10th most found cancer in the US4 and represents about 3.5% of all new cancer diagnoses, and 7.1% of all cancer deaths in the EU5. Surgical resection is the only potential curative treatment for PDAC, but it's feasible for only 15-20% of patients at diagnosis due to the advanced stage of their disease6. Even with successful surgery, the prognosis remains poor, with a high likelihood of recurrence. Advances in neoadjuvant therapies, which are treatments given before surgery, have improved the chances of achieving a margin-negative resection, meaning no cancer cells are found at the outer edge of the removed tissue. However, long-term survival rates remain low, underscoring the need for continued research and development of more effective systemic therapies to improve outcomes for patients with resected PDAC7. ABOUT GERCOR GERCOR is a multidisciplinary association dedicated to clinical research in oncology whose purpose is to improve the care of patients affected by cancer by developing clinical research in the scope of an independent, multidisciplinary and multi-focused cooperative group. GERCOR concentrates its efforts on only one mission: clinical research. Thanks to its network, GERCOR offers patients easy access to its up-to-date treatments. To achieve this goal, GERCOR has all the logistical structure needed to carry out the trials it promotes. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 FOLFIRI: A combination chemotherapy with folinic acid, fluorouracil and irinotecan2 FOLFIRINOX: A combination chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin3 Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes | Journal of Gastrointestinal Cancer4 American Cancer Society: Annual Cancer Facts & Figures | American Cancer Society | American Cancer Society5 European Network of Cancer Registries: Pancreatic_Cancer_2022_ENG.pdf6 A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma | BMC Cancer | Full Text7 A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma | BMC Cancer | Full Text Attachments EN_250602_Post ASCO_vf EN_250602_Post ASCO_vfError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data